Evidence map›Paper›PMID 30053647›Full record

ArticleBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation2018

Catheter-Related Thrombosis in Patients with Lymphoma or Myeloma Undergoing Autologous Stem Cell Transplantation.

Livia Hegerova, Adam Bachan, Qing Cao, Huong X Vu, John Rogosheske, Mark T Reding, Claudio G Brunstein, Mukta Arora, Celalettin Ustun, Gregory M Vercellotti and 1 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 18 citations in OpenAlex.

  1. Venous Thromboembolism in Autologous Blood or Marrow Transplantation Survivors: A Report from the Blood or Marrow Transplant Survivor Study.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2019
    Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Risk of Venous Thromboembolism in Multiple Myeloma Patients During the Immediate Peri-Autologous Hematopoietic Cell Transplantation Phase.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Livia HegerovaCenter for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, Washington. Electronic address: hegerova.livia@gmail.com.
Adam BachanDepartment of Medicine, University of Minnesota Medical Center, Minneapolis, Minnesota.
Qing CaoBiostatistics Core, Masonic Cancer Center, University of Minnesota Medical Center, Minneapolis, Minnesota.
Huong X VuDepartment of Clinical Pharmacology, University of Minnesota Medical Center, Minneapolis, Minnesota.
John RogosheskeDepartment of Clinical Pharmacology, University of Minnesota Medical Center, Minneapolis, Minnesota.
Mark T RedingCenter for Bleeding and Clotting Disorders, University of Minnesota Medical Center, Minneapolis, Minnesota; Division of Hematology, Oncology and Transplantation, University of Minnesota Medical Center, Minneapolis, Minnesota.
Claudio G BrunsteinDivision of Hematology, Oncology and Transplantation, University of Minnesota Medical Center, Minneapolis, Minnesota; Blood and Marrow Transplantation Program, University of Minnesota Medical Center, Minneapolis, Minnesota.
Mukta AroraDivision of Hematology, Oncology and Transplantation, University of Minnesota Medical Center, Minneapolis, Minnesota; Blood and Marrow Transplantation Program, University of Minnesota Medical Center, Minneapolis, Minnesota.
Celalettin UstunDivision of Hematology, Oncology and Transplantation, University of Minnesota Medical Center, Minneapolis, Minnesota; Blood and Marrow Transplantation Program, University of Minnesota Medical Center, Minneapolis, Minnesota.
Gregory M VercellottiDivision of Hematology, Oncology and Transplantation, University of Minnesota Medical Center, Minneapolis, Minnesota; Blood and Marrow Transplantation Program, University of Minnesota Medical Center, Minneapolis, Minnesota.
Veronika BachanovaDivision of Hematology, Oncology and Transplantation, University of Minnesota Medical Center, Minneapolis, Minnesota; Blood and Marrow Transplantation Program, University of Minnesota Medical Center, Minneapolis, Minnesota.
University of Minnesota Medical Center · USSwedish Medical Center · US

Funding

Women's CancerP30CA077598 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Jeffrey S. Miller · 1998 to 2026
$100.4M
Trial Design and Biostatistical Support CoreP01CA065493 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI John E. Wagner · 1995 to 2026
$48.2M
University of Minnesota Clinical and Translational Science Institute (UMN CTSI)UL1TR000114 · NCATS · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R · 2012 to 2015
$35.0M
Institutional Career Development CoreKL2TR002492 · NCATS · UNIVERSITY OF MINNESOTA · PI INGBAR, DAVID H · 2018 to 2022
$6.3M
NCATS NIH HHS KL2 TR002492NCATS NIH HHS UL1 TR000114NCI NIH HHS P01 CA065493NCI NIH HHS P30 CA077598
6 · The paper itself

Abstract

Catheter-related thrombosis (CRT) occurs frequently during autologous hematopoietic cell transplantation (AHCT) and data regarding the incidence, risk factors, and management are understudied. We evaluated 789 consecutive patients with lymphoma and myeloma that underwent AHCT over 10 years (2006 to 2016) and detected the incidence of CRT was 6.3%; only 32% of CRT were symptomatic. The majority occurred within 100 days of AHCT (86%) and median time from tunneled line placement to CRT was 44 days (range, 11 to 89 days). Outcomes of these 50 patients with CRT were compared with age- and disease-matched AHCT control subjects to identify risk factors. History of prior venous thromboembolism (VTE) (20.9% versus 7.0%, P = .02) was the only significant risk factor. Treatment with low-molecular-weight heparin was tolerated with rare minor bleeding (4%), although CRT recurrence or extension (10%) and subsequent VTE (12%) were common. CRT did not impact on nonrelapse mortality or risk of relapse; 2-year progression-free survival was 55% in CRT cases versus 54% in control subjects (P = .42). CRT appears to be common in patients with lymphoma and myeloma undergoing AHCT and significantly contributes to morbidity. Further study to determine mitigating strategies and modify risk factors for CRT is warranted.

Indexed as

FemaleHematopoietic Stem Cell TransplantationHumansLymphomaMaleMiddle AgedMultiple MyelomaProspective StudiesRisk FactorsThrombosisTransplantation, AutologousAutologous transplantationCatheter-related thrombosisLymphoma

Identifiers

PMID30053647
PMCPMC6526714
OpenAlexW2883683026

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.